Nexentis Technologies Inc.

N2OFF Inc. is a publicly traded company that recently underwent a significant strategic transformation, rebranding as Nexentis Technologies Inc. and changing its Nasdaq ticker from NITO to NXTS, effective February 26, 2026. Headquartered in Neve Yarak, Israel, the company has pivoted its primary focus towards AI and data-driven computational biotechnology, while its legacy clean technology assets are now considered non-core holdings.

The company's core business is now centered on drug discovery and development through its wholly-owned subsidiary, MitoCareX Bio Ltd. MitoCareX specializes in developing novel therapies for hard-to-treat cancers, such as pancreatic and non-small cell lung cancer, and inflammatory metabolic diseases. This is achieved by targeting proteins within the mitochondrial SLC25 protein family, utilizing MitoCareX's proprietary MITOLINE™ algorithm. N2OFF Inc. also maintains investments in EU-based solar assets, operating under a Ready to Build (RTB) business model, and previously engaged in agri-tech solutions for reducing nitrous oxide emissions and post-harvest treatments through subsidiaries like NTWO OFF Ltd. and Save Foods Ltd.

The rebranding to Nexentis Technologies Inc. signifies a deliberate shift towards becoming a computational biotech platform, following the acquisition of MitoCareX Bio Ltd. in October 2025. This acquisition brought a proprietary discovery engine to target mitochondrial biology for precision oncology and inflammatory metabolic diseases. Dan Sztybel is listed as the CEO.